Drawing for B-BRIDGE

USPTO serial 76664863

B-BRIDGE

Reviewed by CopyMark Law Group

Reg. 3486764Status 710
Filing date
Status date
Registration date
Aug 19, 2008
Examiner
PHAM, LANA H
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with B-BRIDGE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maryam Imam

Maryam Imam LAW OFFICES OF IMAM111 N. Market StreetSuite 1010San Jose, CA 95113

Goods and services

ClassDescriptionStatusFirst use
001Biosciences research products, namely, biochemical mechanisms used for research in the nature of transfection products, namely, quickstep transfection kit comprised of transfection reagents, for research purposes; Polymerase Chain Reaction (PCR) products, enzymes and reagents, namely, Taq deoxyribonucleic acid (DNA) Polymerase, Hot Start DNA Polymerase, deoxynucleotide triphosphate (dNTP) solutions, namely, sets of all four dNTPs 2'-Deoxyadenosine 5'-Triphosphate (dATP), 2'-Deoxycytidine 5'-Triphosphate (dCTP), 2'-Deoxyguanosine 5'-Triphosphate (dGTP), and 2'-Deoxythymidine 5'-Triphosphate (dTTP)), and Real Time PCR Kits comprised of chemicals, namely, DNA polymerase, Globin mixture containing glycerol, potassium chloride (KCl), dATP, dCTP, dGTP, dTTP and primers, magnesium chloride (MgCl2), reagents, and blood for research purposes; nucleic acid purification products, namely, plasmid DNA isolation kits comprised of chemicals, namely, transfection reagents for research purposes, ribonucleic acid (RNA) purification kits comprised of chemicals, namely, transfection reagents for research purposes, and high throughput purification kits comprised of chemicals, namely, buffers and buffers for lysis, binding, wash and elute, and mannitol-adenine-phosphate (MAP) solution containing mannitol, adenine and crystalline sodium dihydrogen phosphate for research purposes; apoptosis detection kits comprised of reagents for research purposes and chemicals consisting of buffers, fixatives, and biochemical stains; diabetes and obesity research products, namely, chemicals in the nature of human and mouse/rat adiponectin, resistin, leptin, and leptin-receptor enzyme-linked immunosorbent assay (ELISA) kits comprised of chemicals and anti-human leptin-receptor, wash buffer, recombinant human leptin-receptor, assay diluent, biotinylated anti-human leptin-receptor, concentrated horseradish peroxidase (HRP)-conjugated streptavidin, tetramethylbenzidine (TMB), and sulfuric acid substances for research purposes, and human endogenous secreted receptor for advanced glycation end products (esRAGE); ELISA kit comprised of chemicals in the nature of sulfuric acid, plate with absorbed anti-RAGE antibody, esRAGE intibody-horseradish peroxidase conjugated as Detection Antibody, 3,3', 5, 5'-tetramethylbenzidine and hydrogen peroxide, phosphate buffered saline containing bovine serum albumin, human esRAGE, phosphate buffered saline with Tween 20, for research purposes; interfering ribonucleic acid (RNAi) products, namely, small interfering RNA (siRNA) reagents for scientific research purpose, and GeneNet siRNA libraries and sequences in the nature of polymers for screening genome-wide for genes regulating cellular responses or signaling pathways, identifying potential drug targets or diagnostic markers that inhibit, enhance, or activate a selectable phenotype and finding crucial regulatory genes using routine growth selections or flow sorting; cell culture products, namely, chemicals in the nature of visceral adipocytes, epididymal adipocytes, subcutaneous adipocytes, and osteoclasts; chemicals for use in scientific research preparations, namely, full open reading frame (ORF) clones, full-length clones, sequence verified clones, and genomic clones for applications in protein expression, functional genomics, and functional analysisSECTION 8 - CANCELLEDJan 3, 2002
042Biological research, consulting, and analytical services, provided by scientists, in the nature of analysis of chemicals and biological sequences, sample analysis, ribonucleic acid (RNA) design in the nature of polymer design, small interfering ribonucleic acid (siRNA) design, siRNA synthesis in the nature of synthesis of polymers for scientific research, biological research of cells, cell strain, biochemical mechanisms, antibodies and proteins, apoptosis detection, cell culture, clones, food, and nucleic acid purification; providing of chemical laboratory facilitiesSECTION 8 - CANCELLEDJan 3, 2002

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 20, 2015C8..CANCELLED SEC. 8 (6-YR)—
Aug 19, 2008R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 3, 2008PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 14, 2008NPUBNOTICE OF PUBLICATION—
Apr 30, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Apr 30, 2008CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 30, 2008XAECEXAMINER'S AMENDMENT ENTERED—
Apr 30, 2008GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Apr 30, 2008GNEAEXAMINERS AMENDMENT E-MAILED—
Apr 30, 2008CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 14, 2008ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 14, 2008REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 25, 2008CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 22, 2008CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 31, 2008DOCKASSIGNED TO EXAMINER—
Jan 16, 2008WOAGWITHDRAWAL OF ATTORNEY GRANTED—
Jan 16, 2008WOARTEAS WITHDRAWAL OF ATTORNEY RECEIVED—
Nov 1, 2007ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Oct 29, 2007PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Oct 16, 2007PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Oct 15, 2007CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 12, 2007CNEAEXAMINERS AMENDMENT MAILED—
Oct 11, 2007XAECEXAMINER'S AMENDMENT ENTERED—
Oct 11, 2007CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 11, 2007ACECAMENDMENT FROM APPLICANT ENTERED—
Sep 11, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 7, 2007MAILPAPER RECEIVED—
Aug 27, 2007CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 27, 2007CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 2, 2007ACECAMENDMENT FROM APPLICANT ENTERED—
Aug 2, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 2, 2007ALIEASSIGNED TO LIE—
Jul 19, 2007MAILPAPER RECEIVED—
Apr 23, 2007CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 22, 2007CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2007TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 26, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 26, 2007TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 29, 2007CEPECOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED—
Jan 26, 2007CEAPEXAMINER'S AMENDMENT/PRIORITY ACTION MAILED—
Jan 26, 2007CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
Jan 16, 2007DOCKASSIGNED TO EXAMINER—
Aug 29, 2006MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 25, 2006NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance